SEC Form 4 · accession 0001578850-26-000014
PTC THERAPEUTICS, INC. · PTCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Gregory Almstead
Officer — CHIEF TECHNICAL OPS OFFICER
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 5:20 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001070081
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | M | 23,749 | $25.69 | A | 83,886 | D | |
| Common StockF2 | Jun 22, 2026 | S | 12,130 | $80.61 | D | 71,756 | D | |
| Common StockF3 | Jun 22, 2026 | S | 11,619 | $81.21 | D | 60,137 | D | |
| Common Stock | holding | — | — | — | 2,737 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $25.69 | Jun 22, 2026 | M | 23,749 | D | — | Feb 14, 2034 | Common Stock | 23,749 | 23,751 | D |
Explanation of responses
- F1This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
- F2This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $80.00 to $80.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $81.00 to $81.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.